Danielle Elyse Antin-Ozerkis MD

Associate Professor of Medicine (Pulmonary)

Clinical Interests

Interstitial Lung Diseases (ILD) including all of the following: Idiopathic Pulmonary Fibrosis (IPF), sarcoidosis, connective tissue disease/autoimmune disease associated ILD (including rheumatoid arthritis, scleroderma, lupus, polymyositis/ dermatomyositis); hypersensitivity pneumonitis; Bronchiolitis Obliterans Organizing Pneumonia (BOOP)/Cryptogenic Organizing Pneumonia (COP); asbestosis; silicosis; Non-Specific Interstitial Pneumonia (NSIP); Respiratory Bronchiolitis-Associated ILD (RB-ILD); Desquamative Interstitial Pneumonia (DIP); Lymphocytic Interstitial Pneumonia (LIP); pulmonary alveolar proteinosis; Lymphangioleiomyomatosis (LAM); bronchiolitis; eosinophilic pneumonias; Wegener's granulomatosis

Board Certifications

Critical Care Medicine (Internal Medicine), Board Certified

Patient Care Locations


Clinical Trials

ConditionsStudy Title
Alpha 1 Antitrypsin Deficiency and AATD(GRADS)(A) - Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis
Sarcoidosis(GRADS)(B) - Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidsosis
Idiopathic Pulmonary Fibrosis(RAINIER) A Phase 2, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Assess the Efficacy and safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (GS-US-322-027)
Pulmonary Fibrosis(BMS-IM136003) Clinical protocol IM136003 and efficacy of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of the safety and efficacy of BMS-986020 in subjects with IPF
Idiopathic Pulmonary Fibrosis(GB28547) A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis

More Clinical Trials...

Edit Profile